Graphic: Cathleen Heard Twenty years ago, venture capitalists knew little about biotechnology. The scientific community knew only a fraction more. "With respect to immune system hormones, not a single interleukin gene had been cloned by 1981. No cytokine had actually been purified to molecular homogeneity," writes Steven Gillis, chairman and CEO of Corixa Corp., a Seattle-based immunotherapeutics company.1 Gillis recollects that preclinical efficacy data in animals did not exist for the earliest
| Graphic: Cathleen Heard |
 |
"Naïvete was a wonderful catalyst for the birth of the biotechnology revolution," Gillis recalls in the same article. "Scientist entrepreneurs knew little of the technological pitfalls ... likewise, investors had little appreciation for the rigors of clinical trials, the politics of the Food and Drug Administration [FDA] advisory panels, and the massive impact these vagaries would play on their rate of return ...
A citizen science game explores how social choices and networks can influence how an illness moves through a population.
View this Issue
By fine-tuning polishing conditions, scientists attain high titers of infectious lentiviral particles during purification.
Learn how a next-generation platform accelerates biological research by enabling high-throughput, spatially resolved multiomics profiling.
In this webinar, Imogen Binnian will share how AI and gene synthesis technology can accelerate the discovery and validation of novel disease traits.
Real-time imaging enhances fluorescence activated cell sorting (FACS) to help scientists overcome the cost and burden of validation.
Industry-first smart HPLC system to provide authenticated user access verification on onboard touchscreen for superior security.
Setting new standards for intelligent mass detection, sensitivity, and sustainability.
Compact, Powerful, and now Mass Spec-Connected for Superior Analytical Performance
The Wellcome Sanger Institute, Helmholtz Munich, and Parse Biosciences have announced a landmark international collaboration to create a Cancer Plasticity Atlas.
